Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Enhancing SARS-CoV-2 Surveillance through Regular Genomic Sequencing in Spain: The RELECOV Network

  • Vázquez-Morón, Sonia
  • Iglesias-Caballero, María
  • Lepe, José
  • Garcia, Federico
  • Melón, Santiago
  • Marimon, José
  • García de Viedma, Darío
  • Folgueira, Maria
  • Galán, Juan
  • López-Causapé, Carla
  • Benito-Ruesca, Rafael
  • Alcoba-Florez, Julia
  • Gonzalez Candelas, Fernando
  • Toro, María
  • Fajardo, Miguel
  • Ezpeleta, Carmen
  • Lázaro, Fernando
  • Pérez Castro, Sonia
  • Cuesta, Isabel
  • Zaballos, Angel
  • Pozo, Francisco
  • Casas, Inmaculada
  • on behalf of RELECOV Network Members
Millions of SARS-CoV-2 whole genome sequences have been generated to date. However, good quality data and adequate surveillance systems are required to contribute to meaningful surveillance in public health. In this context, the network of Spanish laboratories for coronavirus (RELECOV) was created with the main goal of promoting actions to speed up the detection, analyses, and evaluation of SARS-CoV-2 at a national level, partially structured and financed by an ECDC-HERA-Incubator action (ECDC/GRANT/2021/024). A SARS-CoV-2 sequencing quality control assessment (QCA) was developed to evaluate the network’s technical capacity. QCA full panel results showed a lower hit rate for lineage assignment compared to that obtained for variants. Genomic data comprising 48,578 viral genomes were studied and evaluated to monitor SARS-CoV-2. The developed network actions showed a 36% increase in sharing viral sequences. In addition, analysis of lineage/sublineage-defining mutations to track the virus showed characteristic mutation profiles for the Delta and Omicron variants. Further, phylogenetic analyses strongly correlated with different variant clusters, obtaining a robust reference tree. The RELECOV network has made it possible to improve and enhance the genomic surveillance of SARS-CoV-2 in Spain. It has provided and evaluated genomic tools for viral genome monitoring and characterization that make it possible to increase knowledge efficiently and quickly, promoting the genomic surveillance of SARS-CoV-2 in Spain.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells

  • Grau Expósito, Judith|||0000-0001-9350-2429
  • Perea, David|||0000-0003-1562-4740
  • Suppi, Marina|||0000-0002-9042-6659
  • Massana, Núria|||0000-0002-5403-3161
  • Vergara, Ander|||0000-0003-1926-0147
  • Soler, María José|||0000-0003-3621-0766
  • Trinité, Benjamin|||0000-0003-3809-042X
  • Blanco, Julià|||0000-0002-2225-0217
  • García-Pérez, Javier|||0000-0003-0300-1810
  • Alcami, Jose|||0000-0003-0023-7377
  • Serrano-Mollar, Anna|||0000-0002-4990-8162
  • Rosado Rodríguez, Joel|||0000-0001-9308-7827
  • Falcó, Vicenç|||0000-0001-9626-0023
  • Genescà Ferrer, Meritxell|||0000-0001-6413-3812
  • Buzón, Maria José|||0000-0003-4427-9413
The development of physiological models that reproduce SARS-CoV-2 infection in primary human cells will be instrumental to identify host-pathogen interactions and potential therapeutics. Here, using cell suspensions directly from primary human lung tissues (HLT), we have developed a rapid platform for the identification of viral targets and the expression of viral entry factors, as well as for the screening of viral entry inhibitors and anti-inflammatory compounds. The direct use of HLT cells, without long-term cell culture and in vitro differentiation approaches, preserves main immune and structural cell populations, including the most susceptible cell targets for SARS-CoV-2; alveolar type II (AT-II) cells, while maintaining the expression of proteins involved in viral infection, such as ACE2, TMPRSS2, CD147 and AXL. Further, antiviral testing of 39 drug candidates reveals a highly reproducible method, suitable for different SARS-CoV-2 variants, and provides the identification of new compounds missed by conventional systems, such as VeroE6. Using this method, we also show that interferons do not modulate ACE2 expression, and that stimulation of local inflammatory responses can be modulated by different compounds with antiviral activity. Overall, we present a relevant and rapid method for the study of SARS-CoV-2. The early stages of laboratory identification of therapeutics against pathogens is usually based on the use of immortalized cell lines, as exemplified by many studies screening antivirals against SARS-CoV-2. Cell lines are manipulated for their continuous growth which offers several advantages, however they do not fully reproduce the behavior of primary cells nor the complexity of heterogeneous populations. In this study, we overcome this limitation by using surgical resections to establish human lung tissue (HLT) cell cultures ready for drug evaluation. First, we show that HLT preserves lung cell composition, including the main SARS-CoV-2 cellular target, namely alveolar type-2 cells, as well as the proteins required for viral entry into the cells: ACE2, CD147, TMPRSS2 and AXL. Moreover, using HLT cells we identified new antiviral drug candidates missed by conventional systems, and anti-inflammatory compounds that module molecules associated with SARS-CoV-2 infection. In summary, we have established a physiological model that can be used for the identification of novel anti-SARS-CoV-2 therapeutics and other respiratory pathogens.